Nygaard HB, Wagner AF, Bowen GS, Good SP, MacAvoy MG, Strittmatter KA, Kaufman AC,

Rosenberg BJ, Sekine-Konno T, Varma P, Chen K, Koleske AJ, Reiman EM, Strittmatter SM,

Dyck CH (2015) A phase Ib multiple ascending dose study of the safety, tolerability, and central

nervous system availability of AZD0530 (saracatinib) in Alzheimer’s disease. Alz Res Therapy

7:35. https://doi.org/10.1186/s13195-015-0119-0

Oz Y (2019). AACR 2019 – Forward and reverse translational era. Available from https://sms-

oncology.com/news/blog/aacr-2019-forward-and-reverse-translational-era/.

Accessed

29 Aug 2020

Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, Schacht AL (2010)

How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nat Rev

Drug Discov 9:203–214. https://doi.org/10.1038/nrd3078

Payne K, Brooks J, Spruce R, Batis N, Taylor G, Nankivell P, Mehanna H (2019) Circulating

tumour cell biomarkers in head and neck cancer: current Progress and future prospects. Cancers

11:1115. https://doi.org/10.3390/cancers11081115

Reynolds K, Sarangi S, Bardia A, Dizon DS (2014) Precision medicine and personalized breast

cancer: combination pertuzumab therapy. Pharmacogenomics Pers Med 7:95–105. https://doi.

org/10.2147/PGPM.S37100

Rudin CM, Brahmer JM, Juergens RA, Hann CL, Ettinger DS, Sebree R, Smith R, Aftab BT,

Huang P, Liu JO (2013) Phase 2 study of pemetrexed and itraconazole as second-line therapy

for metastatic no squamous non-small-cell lung cancer. J Thorac Oncol 8(5):619–623. https://

doi.org/10.1097/JTO.0b013e31828c3950

Scannell JW, Blanckley A, Boldon H, Warrington B (2012) Diagnosing the decline in pharmaceu-

tical R&D efficiency. Nat Rev Drug Discov 11:191–200. https://doi.org/10.1038/nrd3681

Seyhan AA (2010) Biomarkers in drug discovery and development. Eur Biopharm Rev 5:19–25

Seyhan A (2019) Lost in translation: the valley of death across preclinical and clinical divide –

identification of problems and overcoming obstacles. Transl Med Commun 4:18. https://doi.org/

10.1186/s41231-019-0050-7

Shakhnovich V (2018) It's time to reverse our thinking: the reverse translation research paradigm.

CTS Clin Transl Sci 11:98–99. https://doi.org/10.1111/cts.12538

Simon R (2011) Genomic biomarkers in predictive medicine. An interim analysis. EMBO Mol Med

3:429–435. https://doi.org/10.1002/emmm.201100153

Strimbu K, Tavel JA (2010) What are biomarkers? Curr Opin HIV AIDS 5:463–466. https://doi.

org/10.1097/COH.0b013e32833ed177

Takumi ITO, Hiroshi H (2020) Molecular mechanisms of thalidomide and its derivatives. Proc Jpn

Acad Ser B Phys Biol Sci 96(6):189–203. https://doi.org/10.2183/pjab.96.016

Vogenberg FR, Isaacson Barash C, Pursel M (2010) Personalized medicine: part 1: evolution and

development into theranostics. P T 35:560–576

Wan JCM, Massie C, Garcia CJ, Mouliere F, Brenton JD, Caldas C, Pacey S, Baird R, Rosenfeld N

(2017) Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat

Rev Cancer 17:223–238. https://doi.org/10.1038/nrc.2017.7

Waring SC, Naylor S (2016) The silent epidemic of Alzheimer’s disease: can precision medicine

provide effective drug therapies? J Precision Med 4:38–49. https://doi.org/10.21037/atm.2016.

03.05

Waring MJ, Arrowsmith J, Leach AR, Leeson PD, Mandrell S, Owen RM, Pairaudeau G, Pennie

WD, Pickett SD, Wang J (2015) An analysis of the attrition of drug candidates from four major

pharmaceutical companies. Nat Rev Drug Discov 14:475–486. https://doi.org/10.1038/nrd4609

Woolf SH (2008) The meaning of translational research and why it matters. JAMA 299:211–213.

https://doi.org/10.1001/jama.2007.26

Yin W, Mao C, Luan X, Shen D, Shen Q, Su H, Wang X, Zhou F, Zhao W, Gao M, Chang S, Xie Y,

Tian G, Jiang H, Tao S, Shen J, Jiang Y, Jiang H, Xu Y, Zhang S, Zhang Y, Xu HE (2020)

Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by

remdesivir. Science 368(6498):1499–1504. https://doi.org/10.1126/science.abc1560

140

R. K. Goyal and G. Aggarwal